natgillin/translations-raw huggingface dataset:
Glass vial
injekcijska viala (steklena)
Glass vial
Steklenička
GLASS VIAL
VIALA
Glass vial (type I hydrolytic glass) of 10 ml containing 500; 1,000; 2,500; 5,000 or 10,000 doses closed with a halogenobutyl rubber bung and sealed with a coded aluminium cap.
Steklena viala (steklo I. hidrolitične skupine) po 10 ml, ki vsebuje 500, 1.000, 2.500, 5.000 ali 10.000 odmerkov, zaprta z zamaškom iz halogenbutilne gume in zapečatena z aluminijasto zaporko s šifro.
Glass vial (type I) of 10 ml closed with a nitryl-based rubber stopper and sealed with an aluminium cap.
Steklena viala (tip I) z 10 ml, zaprta z nitrilnim gumijastim zamaškom in zavarjena z aluminijasto zaporko
Glass vial / Solution for injection
Steklena viala / Raztopina za injiciranje
Glass vial 10 ml
10-mililitrska steklena viala
Glass vial 100 ml and 250 ml
Steklena viala 100 ml in 250 ml
Glass vial 50 ml
Steklena viala 50 ml
Glass vial closed rubber stopper and aluminium cap
Steklena viala zaprta z gumijastim zamaškom in aluminijasto zaporko
Glass vial label for 10 ml
Steklena viala – nalepka za 10 ml
Glass vial label for 50 ml and 100 ml
Steklena viala – nalepka za 50 ml in 100 ml
Glass vial of 1 or 50 doses closed with a halogenobutyl rubber stopper and aluminium cap.
Viala z 1 ali 50 odmerki z zamaškom iz halogenbutilne gume in aluminijasto zaporko.
Glass vial of 10 ml
10-mililitrska steklena viala
Glass vial of 3 ml containing the adjuvanted liquid, with a 13 mm-diameter butyl elastomer stopper and set with an aluminium capsule.
3 mililitrska steklena viala ki vsebuje tekočino z dodatki, z zamaškom iz butil elastomera, premera 13 mm, ter komplet z aluminijasto kapsulo.
GLASS VIAL Scintimun
STEKLENA VIALA Scintimun
GLASS VIAL Solvent for Scintimun
STEKLENA VIALA Vehikel za zdravilo Scintimun
Glass vial with rubber stopper and aluminium cap
Steklena viala zaprta z gumijastim zamaškom in aluminijasto zaporko
Glass vial with stopper set with an aluminium capsule
Steklena viala z zamaškom ter komplet z kapsulo
Glass vials of 20, 50, 100 and 250 ml.
Steklene viale po 20, 50, 100 in 250 ml.
glass vials with chlorobutyl stopper and aluminium seal
tipa II s klorobutilnim zamaškom in aluminijasto kapico
Glass vials: 20 ml vials, glass type I
Steklene viale: 20 ml viale, steklo tipa I
glass)
jantarjeve barve)
Glatiramer acetate
(0,55; 0,93)
Glatiramer acetate
hipointenzivnih lezij T1 v
Glaucoma
glavkom
glaucoma (increased pressure in the eye)
glavkom (zvišan tlak v očesu),
glaucoma (increased pressure within the eyeball), increased tears, redness of the eyes, problems with movement of your eyes, eye rolling
glavkom (zvečan tlak v notranjosti očesa), zvečano solzenje, rdeče oči, težave pri premikanju oči, zavijanje z očmi
glaucoma (increased pressure within the eyeball), problems with movement of your eyes, eye rolling
glavkom (zvišan tlak v notranjosti očesa), težave pri premikanju oči, zavijanje z očmi
glaucoma (increased pressure within the eyeball), problems with movement of your eyes, eye rolling, oversensitivity of the eyes to light, increased tears, redness of the eyes
glavkom (zvečan tlak v notranjosti očesa), težave pri premikanju oči, zavijanje z očmi preobčutljivost na svetlobo, zvečano solzenje, rdeče oči
Glaucoma,
glavkom,
Glaucoma,
hiperemija,
glaucoma, eye movement
glavkom, motnja premikanja oči,
glaucoma, eye movement disorderc, eye rollingc, lacrimation increased, ocular hyperaemia
glavkom, motnja premikanja očic, obračanje očic, povečano solzenje, očesna hiperemija
Glaucoma.
Glavkom.
Glaucoma1
glavkom1
glaucoma;
gavkom
glaucoma;
glavkom
glaucoma;
glavkom;
glaucomae, eye movement disorder, eye rolling, photophobia, lacrimation increased, ocular hyperaemia
glavkome, motnja premikanja oči, obračanje oči, fotofobija, povečano solzenje, očesna hiperemija
Glaxo Group Limited
Glaxo Group Limited 980 Great West Road Brentford
Glaxo Group Limited 980 Great West Road Brentford
980 Great West Road, Brentford,
Glaxo Group Limited, 980 Great West Road, Brentford, Middlesex TW8 9GS United Kingdom.
Glaxo Group Limited, 980 Great West Road, Brentford, Middlesex TW8 9GS, Velika Britanija.
Glaxo Group Limited, 980 Great West Road, Brentford, Middlesex TW8 9GS, United Kingdom.
Glaxo Group Limited, 980 Great West Road, Brentford, Middlesex TW8 9GS, Velika Britanija.
Glaxo Group Limited, 980 Great West Road, Brentford, Middlesex, TW8 9GS United Kingdom Glaxo Group Ltd logo
Glaxo Group Limited, 980 Great West Road, Brentford, Middlesex, TW8 9GS, Velika Britanija Glaxo Group Ltd logo
Glaxo Group Limited, 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom Glaxo Group Ltd logo
Glaxo Group Limited, 980 Great West Road, Brentford, Middlesex, TW8 9GS, Velika Britanija Glaxo Group Ltd logo
Glaxo Group Ltd, 980 Great West Road, Brentford, Middlesex TW8 9GS, United Kingdom
Glaxo Group Ltd, 980 Great West Road, Brentford, Middlesex TW8 9GS, Velika Britanija
Glaxo Group Ltd, 980 Great West Road, Brentford, Middlesex TW8 9GS, United Kingdom
Glaxo Group Ltd, 980 Great West Road, Brentford, Middlesex, TW8 9GS, Velika Britanija
Glaxo Group Ltd, 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom Manufacturer:
Glaxo Group Ltd, 980 Great West Road, Brentford, Middlesex, TW8 9GS, Velika Britanija Izdelovalec:
Glaxo Group Ltd, Greenford, Middlesex, UB6 0NN, United Kingdom
Glaxo Group Ltd, Greenford, Middlesex, UB6 0NN, Velika Britanija
Glaxo Operations UK Limited (Trading as Glaxo Wellcome Operations) Harmire Road
Glaxo Operations UK Limited (posluje kot Glaxo Wellcome Operations)
Glaxo Operations UK Limited (Trading as Glaxo Wellcome Operations), Harmire Road, Barnard Castle, County Durham, DL12 8DT, United Kingdom.
Glaxo Operations UK Limited (Trading as Glaxo Wellcome Operations), Harmire Road, Barnard Castle, County Durham, DL12 8DT, Velika Britanija
Glaxo Operations UK Limited (trading as Glaxo Wellcome Operations): Harmire Road, Barnard Castle, County Durham DL12 8DT, United Kingdom.
Glaxo Operations UK Limited (trading as Glaxo Wellcome Operations): Harmire Road, Barnard Castle, County Durham DL12 8DT, Velika Britanija
Glaxo Operations UK Limited, trading as Glaxo Wellcome Operations Priory Street, Ware, Hertfordshire SG12 ODJ, United Kingdom
Glaxo Operations UK Limited, trži Glaxo Wellcome Operations Priory Street, Ware, Hertfordshire SG12 ODJ, Velika Britanija
Glaxo Operations UK Ltd
Glaxo Wellcome UK Ltd
Glaxo Operations UK Ltd (trading as Glaxo Wellcome Operations) Harmire Road
Glaxo Operations UK Ltd(pod imenom Glaxo Wellcome Operations) Harmire Road
Glaxo Operations UK Ltd. (trading as Glaxo Wellcome Operations) Priory Street‌
Glaxo Operations UK Ltd. (posluje kot Glaxo Wellcome Operations) Priory Street
Glaxo Operations UK, Ltd,(trading as Glaxo Wellcome Operations) Harmire Road
Glaxo Operations UK Ltd (pod imenom Glaxo Wellcome Operations) Harmire Road
Glaxo Wellcome GmbH & Co. KG
Glaxo Wellcome GmbH & Co, KG
Glaxo Wellcome House Berkeley Avenue Greenford
Glaxo Wellcome House Barkeley Avenue Greenford
Glaxo Wellcome House Berkeley Avenue Greenford
Glaxo Wellcome House Berkeley Avenue Greenford Middlesex UB6 0NN
Glaxo Wellcome Production, 1 rue de l'Abbaye, F-76960 Notre Dame de Bondeville, France.
Glaxo Wellcome Production, 1 rue de l'Abbaye, F-76960 Notre Dame de Bondeville, Francija
Glaxo Wellcome S.A., Avenida de Extremadura 3, 09400 Aranda de Duero Burgos, Spain.
Glaxo Wellcome S.A., Avenida de Extremadura 3, 09400 Aranda de Duero Burgos, Španija
GlaxoSmithKline (GSK) S.R.L. Tel: + 4021 3028 208
Tel: + 385 1 6051 999
GlaxoSmithKline (GSK) SRL Tel: +40 (0)21 3028 208
GlaxoSmithKline (GSK) SRL Tel: + 40 (0)21 3028 208 grippeA@gsk.com
GlaxoSmithKline Biologicals S.A. 89 rue de I’Institut-1330 Rixensart Belgium
GlaxoSmithKline Biologicals S.A. 89 rue de I’Institut-1330 Rixensart Belgija
GlaxoSmithKline Latvia SIA Tel: + 371 67312687 lv-epasts@gsk.com
GlaxoSmithKline (Cyprus) Ltd Τηλ: + 357 22 39 70 00 gskcyprus@gsk.com
GlaxoSmithKline Manufacturing S.P.A. Strada Provinciale Asolana No.
GlaxoSmithKline Manufacturing S.P.A. Provinciale Asolana No.
GlaxoSmithKline Pharma A/S Tlf: + 45 36 35 91 00
GlaxoSmithKline Pharma A/S Tlf: + 45 36 35 91 00 dk-med-info@gsk.com
GlaxoSmithKline Pharma GmbH Tel: + 43 (0)1 97075 0 at.info@gsk.com
Tel.: + 48 (0)22 576 9000
GlaxoSmithKline Trading Services Limited Currabinny
GlaxoSmithKline Trading Services Limited Currabinny,
GlaxoSmithKline Trading Services Limited, Currabinny,
GlaxoSmithKline Trading Services Limited,
glibenclamide, metformin, repaglinide – used to treat diabetes
glibenklamid, metformin, repaglinid – uporabljajo se za zdravljenje sladkorne bolezni,
Glibenclamide: co-administration of bosentan 125 mg twice daily for 5 days decreased the plasma concentrations of glibenclamide (a CYP3A4 substrate) by 40%, with potential significant decrease of the hypoglycaemic effect.
Glibenklamid: pri sočasni uporabi bosentana v odmerku 125 mg dvakrat na dan 5 dni se je plazemska koncentracija glibenklamida (substrat CYP3A4) znižala za 40 % in potencialno pomembno zmanjšala hipoglikemični učinek.
Glidipion 15 mg tablets are white, round, flat, bevelled, 5.5 mm in diameter and engraved with ‘TZ15’ on one side.
Tablete Glidipion 15 mg so bele, okrogle, ploščate, na obeh straneh izbočene tablete s premerom 5,5 mm, ki imajo na eni strani vtisnjeno oznako 'TZ15'.
Glidipion 15 mg, 30 mg and 45 mg tablets Glidipion 15 mg tablets Glidipion 30 mg tablets Glidipion 45 mg tablets
Glidipion 15 mg, 30 mg in 45 mg tablete Glidipion 15 mg tablete Glidipion 30 mg tablete Glidipion 45 mg tablete
Glidipion 30 mg tablets are white, round, flat, bevelled, 7 mm in diameter and engraved with ‘TZ30’ on one side.
Tablete Glidipion 30 mg so bele, okrogle, ploščate, na obeh straneh izbočene tablete s premerom 7 mm, ki imajo na eni strani vtisnjeno oznako 'TZ30'.
Glidipion 30 mg tablets pioglitazone
Glidipion 15 mg tablete pioglitazon
Glidipion 45 mg tablets are white, round, flat, bevelled, 8 mm in diameter and engraved with ‘TZ45’ on one side.
Tablete Glidipion 45 mg so bele, okrogle, ploščate, na obeh straneh izbočene tablete s premerom 8 mm, ki imajo na eni strani vtisnjeno oznako 'TZ45'.
Glidipion 45 mg tablets pioglitazone
220 Hafnarfjörđur Islandija
Glidipion can also be used in combination with metformin in patients who are not satisfactorily controlled on metformin alone, or with a sulphonylurea (another type of antidiabetes medicine) when metformin is not suitable (‘dual therapy’).
Lahko se uporablja tudi v kombinaciji z metforminom pri bolnikih, pri katerih zgolj z metforminom ni mogoče doseči zadovoljivega nadzora, ali v kombinaciji s sulfonilsečnino (drugo vrsto zdravila proti sladkorni bolezni), če metformin ni primeren (zdravljenje z dvema zdraviloma).
Glidipion can also be used together with both metformin and a sulphonylurea in patients who are not satisfactorily controlled despite dual therapy by mouth (‘triple therapy’).
Zdravilo Glidipion se lahko uporablja tudi skupaj z metforminom in sulfonilsečnino hkrati pri bolnikih, pri katerih nadzor ni zadosten kljub dvojnemu peroralnemu zdravljenju (zdravljenje s tremi zdravili).
Glidipion contains lactose monohydrate
Zdravilo Glidipion vsebuje laktozo monohidrat
Glidipion is a ‘generic medicine’.
Zdravilo Glidipion je „generično zdravilo“.
Glidipion with food and drink
Zdravilo Glidipion skupaj s hrano in pijačo
Glimepiride 4 mg/day
glimepirid 4 mg/dan
Glimepiride 8 mg/day
glimepirid 8 mg/dan
Glimepiride binds with a high exchange rate to a beta cell membrane protein which is associated with the ATP-sensitive potassium channel but which differs from the usual sulphonylurea binding site.
Glimepirid se z veliko hitrostjo izmenjave veže na membransko beljakovino celic beta, povezano s kalijevimi kanalčki, občutljivimi za ATP, vendar se mesto njegove vezave razlikuje od običajnega mesta vezave sulfonilsečnin.
Glimepiride has a very low distribution volume (approximately 8.8 litres) which is roughly equal to the albumin distribution space, high protein binding (> 99%), and a low clearance (approximately 48 ml/min).
Glimepirid ima zelo nizek volumen porazdelitve (približno 8,8 litrov), kar je približno enako površini porazdelitve albumina, visoko vezavo na beljakovine (99 %) in nizek očistek (približno 48 ml/min).
Glimepiride has been available in the EU since 1995.
Glimepirid je v EU na voljo od leta 1995.
Glimepiride increases the activity of glycosyl-phosphatidylinositol-specific phospholipase C, which may be associated with drug-induced lipogenesis and glycogenesis in isolated fat and muscle cells.
Glimepirid poveča aktivnost za glikozil-fosfatidilinozitol specifične fosfolipaze C. To je morda povezano z indukcijo lipogeneze in glikogeneze, ki jo zdravilo povzroči v izoliranih maščobnih in mišičnih celicah.
Gliolan 30 mg/ml powder for oral solution.
Gliolan 30 mg/ml prašek za peroralno raztopino
Gliolan is indicated in adult patients for visualisation of malignant tissue during surgery for malignant glioma (WHO grade III and IV).
Zdravilo Gliolan je indicirano za vizualizacijo malignega tkiva pri odraslih bolnikih med kirurškim posegom zaradi malignega glioma (III. in IV. stopnje po SZO).
Gliolan is provided in a glass vial and presented in packs of 1, 2 and 10 vials.
Zdravilo Gliolan je na voljo v stekleni viali v pakiranjih po 1, 2 in 10 vial.
Glipizide
glipizid
Glipizide or other “sulfonylureas” (used to treat high blood sugar)
digoksin (uporablja se za zdravljenje srčnega popuščanja), glipizid ali druge sulfonilsečnine (uporabljajo se za zdravljenje zvišanega sladkorja v krvi).
Glipizide or other “sulfonylureas” (used to treat high blood sugar).
digoksin (uporablja se za zdravljenje srčnega popuščanja), glipizid ali druge sulfonilsečnine (uporabljajo se za zdravljenje zvišanega sladkorja v krvi).
Glivec 100 mg capsules are orange to greyish-orange and marked “NVR SI”.
Glivec 100 mg kapsule so oranžne do sivkastooranžne, označene z “NVR SI”.
Glivec 100 mg capsules Imatinib
Glivec 100 mg kapsule imatinib
Glivec 100 mg film-coated tablets are very dark yellow to brownish-orange round tablets.
Glivec 100 mg filmsko obložene tablete so zelo temno rumene do rjavkastooranžne okrogle tablete.
Glivec 100 mg film-coated tablets Imatinib
Glivec 100 mg filmsko obložene tablete imatinib
Glivec 100 mg hard capsules
Glivec 100 mg trde kapsule
Glivec 100 mg hard capsules Imatinib
Glivec 100 mg trde kapsule imatinib
Glivec 100 mg tablets Imatinib
Glivec 100 mg tablete imatinib
Glivec 400 mg film-coated tablets are very dark yellow to brownish-orange oval tablets.
Glivec 400 mg filmsko obložene tablete so zelo temno rumene do rjavkastooranžne ovalne tablete.
Glivec 400 mg film-coated tablets Imatinib
Glivec 400 mg filmsko obložene tablete imatinib
Glivec 400 mg tablets Imatinib
Glivec 400 mg tablete imatinib
Glivec 50 mg capsules are light yellow to orange-yellow and marked “NVR SH”.
Glivec 50 mg kapsule so svetlo rumene do oranžnorumenkaste, označene z “NVR SH”.
Glivec 50 mg capsules Imatinib
Glivec 50 mg kapsule imatinib
Glivec 50 mg hard capsules
Glivec 50 mg trde kapsule
Glivec 50 mg hard capsules Imatinib
Glivec 50 mg trde kapsule imatinib
Glivec is indicated for the treatment of adult and paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment. adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy. adult patients with relapsed or refractory Ph+ ALL as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFR rearrangement.
Zdravilo Glivec je indicirano za zdravljenje odraslih in pediatričnih bolnikov z na novo diagnosticirano kronično mieloično levkemijo (KML), s prisotnim kromosomom Philadelphia (bcr-abl) (Ph+), pri katerih presaditev kostnega mozga kot zdravljenje prve izbire ne pride v poštev; odraslih in pediatričnih bolnikov s Ph+ KML v kronični fazi po neuspelem zdravljenju z interferonom alfa, ali v pospešeni fazi ali blastni krizi; odraslih in pediatričnih bolnikov z na novo diagnosticirano akutno limfoblastno levkemijo, s prisotnim kromosomom Philadelphia (Ph+ ALL) skupaj s kemoterapijo; odraslih bolnikov z relapsom ali neodzivno Ph+ ALL v monoterapiji; odraslih bolnikov z mielodisplastičnimi/mieloproliferativnimi boleznimi (MDS/MPD) v povezavi s preureditvijo genov za receptor za rastni faktor iz trombocitov (PDGFR – platelet derived growth factor receptor); odraslih bolnikov z napredovalim hipereozinofilnim sindromom (HES) ali s kronično eozinofilno levkemijo (CEL) s premestitvijo FIP1L1-PDGFR ali z obojim.
Glivec is indicated for the treatment of adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST). the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST.
Zdravilo Glivec je indicirano za zdravljenje odraslih bolnikov z neresektabilnimi in/ali metastatskimi malignimi gastrointestinalnimi stromalnimi tumorji (GIST), pozitivnimi na Kit (CD 117); adjuvantno zdravljenje odraslih bolnikov s precejšnjim tveganjem za relaps po resekciji GIST, pozitivnega na Kit (CD117).
Glivec is used to treat adults with GIST that cannot be removed with surgery or have spread to other parts of the body, and adults who are at risk of GIST coming back after surgical removal; dermatofibrosarcoma protuberans (DFSP), a type of cancer (sarcoma) in which cells in the tissue beneath the skin divide uncontrollably.
Zdravilo Glivec se uporablja za zdravljenje odraslih z GIST, ki ga ni mogoče kirurško odstraniti ali ki se je razširil v druge dele telesa, in odraslih, pri katerih obstaja tveganje za ponovitev GIST po kirurški odstranitvi. protuberantnega dermatofibrosarkoma (DFSP), tj. vrste raka (sarkoma), pri katerem se celice v tkivu pod kožo nenadzorovano delijo.
Glivec is used to treat adults with HES or CEL who have a specific re-arrangement of two genes called FIP1L1 and PDGFRα; gastrointestinal stromal tumours (GIST), a type of cancer (sarcoma) of the stomach and bowel, when there is uncontrolled growth of cells in the supporting tissues of these organs.
Zdravilo Glivec se uporablja za zdravljenje odraslih s HES ali KEL, ki imajo specifično preureditev dveh genov, imenovanih FIP1L1 in PDGFRα. gastrointestinalnega stromalnega tumorja (GIST), vrste raka (sarkom) želodca in črevesja, kadar celice v opornem tkivu teh organov nenadzorovano rastejo.
Glivec is used to treat adults with MD/MPD who have re-arrangements of the gene for platelet-derived growth factor receptor (PDGFR); advanced hypereosinophilic syndrome (HES) or chronic eosinophilic leukaemia (CEL), diseases in which eosinophils (another type of white blood cell) start growing out of control.
Zdravilo Glivec se uporablja za zdravljenje odraslih z MD/MPD, pri katerih se pojavljajo preureditve gena za receptor za rastni faktor iz trombocitov (PDGFR). napredovalega hipereozinofilnega sindroma (HES) ali kronične eozinofilne levkemije (KEL), tj. bolezni, pri katerih eozinofili (druga vrsta belih krvničk) začnejo nenadzorovano rasti.
Glivec is used when the patients are ‘Philadelphia chromosome positive’ (Ph+).
Zdravilo Glivec se uporablja pri bolnikih s kromosomom Philadelphia (Ph+).
Glivec significantly prolonged RFS, with 75% of patients being recurrence-free at 38 months in the Glivec group vs.
Zdravilo Glivec je statistično značilno podaljšalo preživetje brez ponovitve bolezni, saj je bilo v skupini z zdravilom Glivec 75% bolnikov brez ponovitve bolezni 38 mesecev v primerjavi z
Global health status / health-related quality of life by patient-report were measured using the EORTC Quality of Life Questionnaire – Core 30 (QLQ-C30).
Splošno zdravstveno stanje/kakovost življenja, povezano z zdravjem, po navedbi bolnika so merili z vprašalnikom EORTC QLQ-C30 (Quality of Life Questionnaire – Core 30).
Global Response of Success at EOIVTb
Uspešnost globalnega odziva ob EOIVTb
Global Response of Success at EOTb
Uspešnost globalnega odziva ob EOTb
Global success in the MITT population: primary and secondary endpoints
Globalen uspeh v populaciji MITT: primarni in sekundarni opazovani dogodki
Globally, acute episodes of GvHD occurred in 10 patients (33%) with a median time to onset of 90 days after HSCT and 42 days after last infusion of Zalmoxis cells.
Po vsem svetu so se akutne epizode GvHD pojavile pri 10 bolnikih (33 %) z mediano časa do začetka 90 dni po haploidentični presaditvi krvotvornih matičnih celic in 42 dni po zadnjem infundiranju celic zdravila Zalmoxis.
glomerular filtration rate (CrCL,)
hitrost glomerulne filtracije (CrCl)
Glomerular filtration rate decreased
zmanjšana hitrost glomerulne filtracije
Glomerular filtration rate Dose Frequency
Stopnja hitrosti glomerulne filtracije Odmerek Pogostnost
Glomerulonephri tis
glomerulonefritis
Glomerulonephritis
glomerulonefriti s
Glomerulonephritis, blood creatinine increased
glomerulonefritis, povečana vrednost kreatinina v krvi
Glomerulonephritis, blood creatinine increased
glomerulonefritis, zvišanje ravni kreatinina v krvi
Gloves must be worn when removing IONSYS from the patient’s skin and during disposal.
Pri odstranjevanju sistema IONSYS z bolnikove kože in pri postopku odlaganja je treba nositi rokavice.
Gloves must be worn while removing IONSYS from the skin and care should be taken to avoid touching the hydrogels.
Pri odstranjevanju sistema IONSYS s kože je treba nositi rokavice in paziti, da se ne dotaknete hidrogelov.
Gloves should be worn during the assembly/handling of IONSYS.
Med sestavljanjem sistema IONSYS in ravnanjem z njim je treba nositi rokavice.
Gloves should be worn when handling the product.
Med rokovanjem z zdravilom je treba nositi rokavice.
Gloves should be worn when handling the product.
Pri rokovanju z zdravilom za uporabo v veterinarski medicini je treba nositi rokavice.
Gloves should be worn when handling the veterinary medicinal product.
Pri rokovanju z zdravilom za uporabo v veterinarski medicini je treba nositi rokavice.
Gloves should be worn when manipulating IONSYS.
Med ravnanjem z zdravilom IONSYS je treba nositi rokavice.
Gloves: for hands, wrist and fingers.
Rokavice: za roke, zapestja in prste.
GLP-1 receptor agonist
agonist receptorjev GLP-1
GLP­1 is a physiological regulator of appetite and food intake, but the exact mechanism of action is not entirely clear.
GLP-1 je fiziološki regulator apetita in vnosa hrane, vendar pa natančen mehanizem delovanja ni v celoti znan.
Glubrava
Zdravilo Glubrava
Glubrava 15 mg/850 mg film-coated tablets
Glubrava 15 mg/850 mg filmsko obložene tablete
Glubrava 15 mg/850 mg film-coated tablets Pioglitazone/Metformin hydrochloride
Glubrava 15 mg/850 mg filmsko obložene tablete pioglitazon/metforminijev klorid
Glubrava 15 mg/850 mg tablets
Glubrava 15 mg/850 mg tablete
Glubrava 15 mg/850 mg tablets Pioglitazone/Metformin hydrochloride
Glubrava 15 mg/850 mg tablete pioglitazon/metforminijev klorid
Glubrava combines two antihyperglycaemic active substances with complementary mechanisms of action to improve glycaemic control in patients with type 2 diabetes: pioglitazone, a member of the thiazolidinedione class and metformin hydrochloride, a member of the biguanide class.
Zdravilo Glubrava je kombinacija dveh antihiperglikemičnih učinkovin s komplementarnim mehanizmom delovanja, namenjeno pa je izboljšanju urejenosti glikemije pri bolnikih s sladkorno boleznijo tipa 2: pioglitazona iz skupine tiazolidindionov in metforminijevega klorida iz skupine bigvanidov.
Glubrava is contraindicated in patients with:
Zdravilo Glubrava je kontraindicirano pri:
Glubrava should be discontinued if any deterioration in cardiac status occurs.
Če se pojavi kakršnokoli poslabšanje srčnega statusa, je treba zdravljenje z zdravilom Glubrava ukiniti.